meningococcal vaccine
- Generic Name
- meningococcal vaccine
CDC Advisory Panel Recommends Expanded RSV Vaccination for Adults 50-59 With High-Risk Conditions
• The CDC's Advisory Committee on Immunization Practices voted to recommend RSV vaccination for high-risk adults aged 50-59, potentially benefiting approximately 30% of Americans in this age group with conditions like COPD, heart failure, and chronic kidney disease.
• The panel also endorsed GSK's new pentavalent meningococcal vaccine (MenABCWY) and Bavarian Nordic's chikungunya vaccine (Vimkunya) for travelers to outbreak regions and laboratory workers.
• Implementation of these recommendations faces uncertainty due to CDC leadership transitions, with potential decisions falling to Health Secretary Robert F. Kennedy Jr. in the absence of a confirmed CDC director.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath